Boothbay Fund Management’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-86,700
Closed -$2.56M 1724
2025
Q1
$2.56M Sell
86,700
-29,400
-25% -$916K 0.07% 374
2024
Q4
$3.38M Buy
+116,100
New +$4.85M 0.08% 318

Other funds holding RNAM

Boothbay Fund Management's RNAM Position: Q1 2026 in Review

Boothbay Fund Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 60,582 shares — an estimated $4.37M sold.

Boothbay Fund Management first reported a position in RNAM in Q2 2025 and held it in 3 quarters. The position peaked at $4.37M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Boothbay Fund Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 60,582 Avidity Biosciences shares in Q1 2026, an estimated $4.37M.
  • Boothbay Fund Management first reported a position in Avidity Biosciences in Q2 2025 and held it in 3 quarters.
  • Boothbay Fund Management's Avidity Biosciences position peaked at $4.37M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.